Cargando…

Intracerebral gadolinium deposition following blood–brain barrier disturbance in two different mouse models

To evaluate the influence of the blood–brain barrier on neuronal gadolinium deposition in a mouse model after multiple intravenous applications of the linear contrast agent gadodiamide. The prospective study held 54 mice divided into three groups: healthy mice (A), mice with iatrogenic induced distu...

Descripción completa

Detalles Bibliográficos
Autores principales: Kromrey, M. L., Oswald, S., Becher, D., Bartel, J., Schulze, J., Paland, H., Ittermann, T., Hadlich, S., Kühn, J. P., Mouchantat, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10287697/
https://www.ncbi.nlm.nih.gov/pubmed/37349374
http://dx.doi.org/10.1038/s41598-023-36991-8
_version_ 1785061928208433152
author Kromrey, M. L.
Oswald, S.
Becher, D.
Bartel, J.
Schulze, J.
Paland, H.
Ittermann, T.
Hadlich, S.
Kühn, J. P.
Mouchantat, S.
author_facet Kromrey, M. L.
Oswald, S.
Becher, D.
Bartel, J.
Schulze, J.
Paland, H.
Ittermann, T.
Hadlich, S.
Kühn, J. P.
Mouchantat, S.
author_sort Kromrey, M. L.
collection PubMed
description To evaluate the influence of the blood–brain barrier on neuronal gadolinium deposition in a mouse model after multiple intravenous applications of the linear contrast agent gadodiamide. The prospective study held 54 mice divided into three groups: healthy mice (A), mice with iatrogenic induced disturbance of the blood–brain barrier by glioblastoma (B) or cerebral infarction (C). In each group 9 animals received 10 iv-injections of gadodiamide (1.2 mmol/kg) every 48 h followed by plain T1-weighted brain MRI. A final MRI was performed 5 days after the last contrast injection. Remaining mice underwent MRI in the same time intervals without contrast application (control group). Signal intensities of thalamus, pallidum, pons, dentate nucleus, and globus pallidus-to-thalamus and dentate nucleus-to-pons ratios, were determined. Gadodiamide complex and total gadolinium amount were quantified after the last MR examination via LC–MS/MS and ICP-MS. Dentate nucleus-to-pons and globus pallidus-to-thalamus SI ratios showed no significant increase over time within all mice groups receiving gadodiamide, as well as compared to the control groups at last MR examination. Comparing healthy mice with group B and C after repetitive contrast administration, a significant SI increase could only be detected for glioblastoma mice in globus pallidus-to-thalamus ratio (p = 0.033), infarction mice showed no significant SI alteration. Tissue analysis revealed significantly higher gadolinium levels in glioblastoma group compared to healthy (p = 0.013) and infarction mice (p = 0.029). Multiple application of the linear contrast agent gadodiamide leads to cerebral gadolinium deposition without imaging correlate in MRI.
format Online
Article
Text
id pubmed-10287697
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-102876972023-06-24 Intracerebral gadolinium deposition following blood–brain barrier disturbance in two different mouse models Kromrey, M. L. Oswald, S. Becher, D. Bartel, J. Schulze, J. Paland, H. Ittermann, T. Hadlich, S. Kühn, J. P. Mouchantat, S. Sci Rep Article To evaluate the influence of the blood–brain barrier on neuronal gadolinium deposition in a mouse model after multiple intravenous applications of the linear contrast agent gadodiamide. The prospective study held 54 mice divided into three groups: healthy mice (A), mice with iatrogenic induced disturbance of the blood–brain barrier by glioblastoma (B) or cerebral infarction (C). In each group 9 animals received 10 iv-injections of gadodiamide (1.2 mmol/kg) every 48 h followed by plain T1-weighted brain MRI. A final MRI was performed 5 days after the last contrast injection. Remaining mice underwent MRI in the same time intervals without contrast application (control group). Signal intensities of thalamus, pallidum, pons, dentate nucleus, and globus pallidus-to-thalamus and dentate nucleus-to-pons ratios, were determined. Gadodiamide complex and total gadolinium amount were quantified after the last MR examination via LC–MS/MS and ICP-MS. Dentate nucleus-to-pons and globus pallidus-to-thalamus SI ratios showed no significant increase over time within all mice groups receiving gadodiamide, as well as compared to the control groups at last MR examination. Comparing healthy mice with group B and C after repetitive contrast administration, a significant SI increase could only be detected for glioblastoma mice in globus pallidus-to-thalamus ratio (p = 0.033), infarction mice showed no significant SI alteration. Tissue analysis revealed significantly higher gadolinium levels in glioblastoma group compared to healthy (p = 0.013) and infarction mice (p = 0.029). Multiple application of the linear contrast agent gadodiamide leads to cerebral gadolinium deposition without imaging correlate in MRI. Nature Publishing Group UK 2023-06-22 /pmc/articles/PMC10287697/ /pubmed/37349374 http://dx.doi.org/10.1038/s41598-023-36991-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Kromrey, M. L.
Oswald, S.
Becher, D.
Bartel, J.
Schulze, J.
Paland, H.
Ittermann, T.
Hadlich, S.
Kühn, J. P.
Mouchantat, S.
Intracerebral gadolinium deposition following blood–brain barrier disturbance in two different mouse models
title Intracerebral gadolinium deposition following blood–brain barrier disturbance in two different mouse models
title_full Intracerebral gadolinium deposition following blood–brain barrier disturbance in two different mouse models
title_fullStr Intracerebral gadolinium deposition following blood–brain barrier disturbance in two different mouse models
title_full_unstemmed Intracerebral gadolinium deposition following blood–brain barrier disturbance in two different mouse models
title_short Intracerebral gadolinium deposition following blood–brain barrier disturbance in two different mouse models
title_sort intracerebral gadolinium deposition following blood–brain barrier disturbance in two different mouse models
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10287697/
https://www.ncbi.nlm.nih.gov/pubmed/37349374
http://dx.doi.org/10.1038/s41598-023-36991-8
work_keys_str_mv AT kromreyml intracerebralgadoliniumdepositionfollowingbloodbrainbarrierdisturbanceintwodifferentmousemodels
AT oswalds intracerebralgadoliniumdepositionfollowingbloodbrainbarrierdisturbanceintwodifferentmousemodels
AT becherd intracerebralgadoliniumdepositionfollowingbloodbrainbarrierdisturbanceintwodifferentmousemodels
AT bartelj intracerebralgadoliniumdepositionfollowingbloodbrainbarrierdisturbanceintwodifferentmousemodels
AT schulzej intracerebralgadoliniumdepositionfollowingbloodbrainbarrierdisturbanceintwodifferentmousemodels
AT palandh intracerebralgadoliniumdepositionfollowingbloodbrainbarrierdisturbanceintwodifferentmousemodels
AT ittermannt intracerebralgadoliniumdepositionfollowingbloodbrainbarrierdisturbanceintwodifferentmousemodels
AT hadlichs intracerebralgadoliniumdepositionfollowingbloodbrainbarrierdisturbanceintwodifferentmousemodels
AT kuhnjp intracerebralgadoliniumdepositionfollowingbloodbrainbarrierdisturbanceintwodifferentmousemodels
AT mouchantats intracerebralgadoliniumdepositionfollowingbloodbrainbarrierdisturbanceintwodifferentmousemodels